BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-eisai-biogen-leqembi-iqlik-pdufa-aug2026@catalyst-calendar.local
DTSTAMP:20260720T200612Z
DTSTART:20260824T040000Z
DTEND:20260824T043000Z
SUMMARY:Leqembi Iqlik皮下注射起始剂量FDA延长审评窗口
DESCRIPTION:Eisai/Biogen的Leqembi Iqlik皮下注射起始剂量sBLA因重大修订延长至2026年8月24日PDUFA；结果影响阿尔茨海默病抗Aβ疗法可及性、给药便利性和商业化曲线。\\nImpact score: 66\\nExpected: FDA批准、延期或要求补充数据；重点在皮下注射起始剂量标签和上市后要求。\\nAffected: ESALY(subject\, unknown\, score 68)\; BIIB(subject\, unknown\, score 66)\; LLY(peer\, mixed\, score 36)\; IBB(etf\, unknown\, score 30)\\nSources: Eisai PDUFA date update: https://www.eisai.com/news/2026/news202625.html\\nBioArctic PDUFA update: https://www.bioarctic.com/en/leqembi-iqlik-pdufa-date-updated-to-august-24-in-the-u-s/\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-eisai-biogen-leqembi-iqlik-pdufa-aug2026
CATEGORIES:fda\,US\,FDA\,PDUFA\,Alzheimer\,antibody
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Leqembi Iqlik皮下注射起始剂量FDA延长审评窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Leqembi Iqlik皮下注射起始剂量FDA延长审评窗口
END:VALARM
END:VEVENT
END:VCALENDAR